Table 3.

Comparison of rates of pCR/RCB-I (pCR plus near-pCR), with 95% confidence intervals (lower panel), among the regimens according to hormone receptor status

Regimen	Overall	P	HR+	P	HR−	P
3-wP/FAC versus wP/FAC	41% versus 57%	0.08	34% versus 47%	0.21	50% versus 68%	0.16
3-wP/FAC versus H + 3-wP/FEC	41% versus 72%	<0.0001	34% versus 73%	0.002	50% versus 72%	0.07
wP/FAC versus H + 3-wP/FEC	57% versus 72%	0.03	47% versus 73%	0.02	68% versus 72%	0.44

	Overall			HR+			HR−
	Mean	95% CI		Mean	95% CI		Mean	95% CI
Treatment groups
H + 3wP/FEC (0)	0.719	0.626	0.812	0.721	0.587	0.855	0.717	0.587	0.848
wP/FAC (1)	0.571	0.449	0.694	0.469	0.296	0.642	0.677	0.513	0.842
3-wP/FAC (2)	0.404	0.264	0.545	0.333	0.156	0.511	0.500	0.281	0.719
Grand total	0.598	0.530	0.666	0.539	0.442	0.636	0.660	0.566	0.754

pCR, pathologic complete response; HR, hormone receptor (estrogen or progesterone receptor); 3-w, 3-weekly; P, paclitaxel; FAC, fluorouracil, doxorubicin, and cyclophosphamide; H, trastuzumab; FEC, fluorouracil, epirubicin, and cyclophosphamide; CI, confidence interval.